News & Updates

Treatment with patritumab deruxtecan (HER3-DXd) confers survival benefits on patients with epidermal growth factor receptor (EGFR)-mutated nonsmall-cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy, results of a phase I study have shown.

Neoadjuvant pembrolizumab plus chemotherapy improves event-free survival (EFS) in high-risk, early-stage triple-negative breast cancer (TNBC) patients with residual cancer burden (RCB), suggests a study.

Dropping aspirin for ticagrelor monotherapy 1 month after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) is as good as dual antiplatelet therapy (DAPT) in the ULTIMATE-DAPT* trial presented at ACC.24.

Dual therapy with vonoprazan and amoxicillin (VA-dual) for 10 days results in a 90.8-percent eradication rate of Helicobacter pylori (H pylori) and fewer adverse events (AEs) compared with the standard 14-day bismuth-based quadruple therapy (B-quadruple), a study has shown.

Olanzapine appears to be just as effective as fosaprepitant, a neurokinin-1 receptor antagonist (NK1-RA), in controlling chemotherapy-induced nausea and vomiting (CINV) in patients with gynaecologic malignancies who were receiving carboplatin/paclitaxel chemotherapy every 3 weeks, a prospective study presented at SGO 2024 suggests. However, the former trumps the latter in terms of cost effectiveness.